ATRC CEO Michael Carrel reports charitable gift of 6,000 shares

Rhea-AI Filing Summary

AtriCure, Inc. CEO and President Michael H. Carrel, who also serves as a director, reported a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025, according to a Form 4 filing. The transaction used code “G,” indicating a gift, and was reported at a price of $0, with the filing noting that no consideration was received for this transfer.

After the reported transaction, Carrel beneficially owns 691,377 shares of AtriCure common stock directly. The filing also lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with a statement that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Insider Trade Summary

6,000 shares gifted

Mixed 3 txns

Insider CARREL MICHAEL H

Role President, CEO, & Director

Type	Security	Shares	Price	Value
Gift	Common Stock	6,000	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 691,377 shares (Direct); Common Stock — 9,310 shares (Indirect, Held by reporting person's children)

Footnotes (1)

1. No consideration was received in connection with this charitable gift. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARREL MICHAEL H

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO, & Director

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		G	V	6,000	D	$0(1)	691,377	D
Common Stock								9,310	I	Held by reporting person's children(2)
Common Stock								2,250	I	Held by reporting person's parents(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. No consideration was received in connection with this charitable gift.

2. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Remarks:

	/s/ Michael H. Carrel	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AtriCure (ATRC) report in this Form 4?

The Form 4 reports that Michael H. Carrel, AtriCure’s President, CEO, and director, made a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025.

At what price were the 6,000 AtriCure (ATRC) shares transferred?

The filing shows the 6,000 shares of AtriCure common stock with a transaction price of $0, and explains that no consideration was received because the transfer was a charitable gift.

How many AtriCure (ATRC) shares does Michael H. Carrel own directly after the transaction?

Following the reported gift, Michael H. Carrel beneficially owns 691,377 shares of AtriCure common stock in direct ownership.

What indirect AtriCure (ATRC) holdings are reported for Michael H. Carrel?

The Form 4 lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with Carrel disclaiming beneficial ownership of these shares except for his pecuniary interest.

What is Michael H. Carrel’s role at AtriCure (ATRC)?

Michael H. Carrel is reported as a Director and an Officer, serving as President, CEO, & Director of AtriCure, Inc.

Was the reported AtriCure (ATRC) transaction a purchase or sale?

The transaction is coded “G” on the Form 4, indicating it was a gift of shares, not an open-market purchase or sale.